Impact of Early CMV Reactivation in Cord Blood Stem Cell Recipients in the Current Era
The unique combination of higher incidence of CMV reactivation in the seropositive recipient and lower incidence of graft versus host disease in cord blood (CB) hematopoietic cell transplantation (HCT) permits a valuable design to analyze the impact of CMV reactivation. Data from 1684 patients transplanted with CB between 2003 and 2010 for AML and ALL were analyzed. [Bone Marrow Transplant] Abstract
Visit our reviews page to see a complete list of reviews in the cord blood research field.
Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients
Gamida Cell announced additional positive results with the use of NiCord®, an experimental treatment for patients with high-risk blood cancers. The data was presented in an oral session titled Transplantation of Ex vivo Expanded Umbilical Cord Blood Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days. [Press release from Gamida Cell discussing research presented at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Valencia] Press Release